Low Dose Naltrexone (LDN): Benefits, Dosing, and What the Research Shows

What Is Low Dose Naltrexone?

Naltrexone is an FDA-approved medication that has been in use since 1984. At its standard dose of 50 mg per day, it blocks opioid receptors and is prescribed to help people with opioid or alcohol use disorders reduce cravings and prevent relapse [1]. It has an excellent safety profile and decades of post-market surveillance data.

Low dose naltrexone (LDN) refers to naltrexone taken at roughly 1/10th to 1/100th of the standard dose, typically between 0.5 mg and 4.5 mg. At these doses, the drug behaves very differently than it does at 50 mg. Rather than providing continuous opioid receptor blockade, LDN produces a brief blockade (lasting approximately 4 to 6 hours) followed by a compensatory upregulation of the body’s endogenous opioid system [2].

This “low dose” concept was pioneered in the late 1980s by Dr. Bernard Bihari, a New York physician who observed that his HIV-positive patients showed improved immune function when given very low doses of naltrexone. Since then, clinical interest in LDN has expanded dramatically, with research spanning autoimmune disease, chronic pain, cancer, and neurological conditions [3].

How LDN Works: Three Key Mechanisms

LDN’s therapeutic effects appear to operate through at least three distinct but interconnected pathways. Understanding these mechanisms helps explain why a single medication can have benefits across such a wide range of conditions.

1. The Endorphin Rebound Effect

When you take LDN at bedtime, it briefly blocks opioid receptors for 4 to 6 hours. Your body interprets this as an endorphin deficit and responds by upregulating production of both endorphins (beta-endorphin) and enkephalins (met-enkephalin). By morning, the naltrexone has cleared your system, and your now-elevated endorphin levels are free to bind to opioid receptors without obstruction [4].

This rebound effect matters because endorphins do far more than just reduce pain. Beta-endorphin is a potent immunomodulator that influences natural killer (NK) cell activity, T-cell function, and the balance between pro-inflammatory and anti-inflammatory cytokines. Met-enkephalin (also called opioid growth factor, or OGF) plays a role in cell proliferation regulation and has been studied for its anti-tumor properties [5].

The net result is a sustained increase in your body’s own pain-relieving and immune-regulating molecules, without the dependency risks or side effects associated with exogenous opioid medications.

2. TLR4 Antagonism and Neuroinflammation

Perhaps LDN’s most important mechanism, and the one that has generated the most research interest in recent years, is its action on toll-like receptor 4 (TLR4). TLR4 is found on microglia (the immune cells of the central nervous system) and on peripheral immune cells like macrophages and dendritic cells [6].

When TLR4 is activated, it triggers the release of pro-inflammatory cytokines including interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin-1 beta (IL-1β). Chronic TLR4 activation is implicated in neuroinflammation, central sensitization, and the perpetuation of chronic pain states. LDN blocks TLR4, reducing the production of these inflammatory mediators [7].

This mechanism is distinct from the opioid receptor effects and may explain why LDN helps conditions where neuroinflammation is a primary driver, such as fibromyalgia, chronic fatigue syndrome, and certain neurodegenerative conditions.

3. Immune System Modulation

LDN appears to shift the immune system toward better regulation rather than simply suppressing or stimulating it. Research suggests it can influence the Th1/Th2 balance, promote regulatory T-cell (Treg) activity, and reduce the overproduction of inflammatory cytokines that drives autoimmune pathology [8].

This immunomodulatory action is fundamentally different from conventional immunosuppressive therapies (like methotrexate or biologics) that broadly dampen immune function. LDN seems to restore balance without leaving patients vulnerable to infections, which is one reason it has attracted so much interest in the autoimmune community.

Conditions Where LDN Shows Benefit

Fibromyalgia

Fibromyalgia is one of the most well-studied applications of LDN. A landmark pilot study from Stanford University found that LDN (4.5 mg/day) reduced fibromyalgia pain by more than 30% compared to placebo, with mechanical and heat pain thresholds also improving significantly [9]. A follow-up study from the same group confirmed these findings and identified elevated erythrocyte sedimentation rate (ESR) as a predictor of treatment response, suggesting that patients with higher baseline inflammation may benefit most [10].

The proposed mechanism for fibromyalgia is primarily the TLR4 pathway: by reducing microglial activation and neuroinflammation, LDN may address the central sensitization that drives fibromyalgia symptoms.

Multiple Sclerosis

A pilot trial published in the Annals of Neurology found that LDN (4.5 mg/day) was well tolerated by MS patients and was associated with improved quality of life measures over 8 weeks [11]. A larger randomized, double-blind trial from Iran showed significant improvements in mental health quality of life scores with LDN compared to placebo [12]. While LDN is not positioned as a replacement for disease-modifying therapies, many MS patients and their neurologists use it as an adjunct treatment.

Crohn’s Disease

A small but notable RCT from Penn State found that 4.5 mg of LDN daily produced a clinical response in 89% of Crohn’s patients and full remission in 67%, compared to 40% response and 17% remission with placebo [13]. Endoscopic evaluation showed objective improvement in mucosal healing. A pediatric pilot study found similar response rates with good tolerability [14].

Chronic Pain Syndromes

Beyond fibromyalgia, LDN has shown promise for complex regional pain syndrome (CRPS), chronic low back pain, and neuropathic pain conditions. The TLR4 mechanism is thought to be the primary driver here, reducing the glial cell activation that maintains chronic pain states. A 2014 review concluded that LDN represents a “novel anti-inflammatory treatment” for chronic pain with a favorable side effect profile compared to conventional analgesics [15].

Other Conditions Under Investigation

Research is ongoing for LDN in a variety of other conditions:

• Hashimoto’s thyroiditis: Preliminary data suggests LDN may reduce thyroid antibody levels and improve thyroid function in some patients [16]
• Rheumatoid arthritis: Case reports and small series show reduced disease activity scores
• Depression: The endorphin-boosting effects of LDN have led to interest in its antidepressant potential, with some studies exploring ultra-low-dose naltrexone as an augmentation strategy
• Cancer: The OGF-OGFr (opioid growth factor receptor) pathway has been studied for anti-proliferative effects in pancreatic, colon, and ovarian cancers, though this research is still in early stages [17]
• Long COVID: Several case series have reported improvements in fatigue, brain fog, and post-exertional malaise with LDN, prompting formal clinical trials [18]

LDN Dosing Protocols

The Standard Titration Approach

Most clinicians start LDN at a low dose and titrate upward gradually. A common protocol:

• Week 1-2: 0.5 mg at bedtime
• Week 3-4: 1.0 mg at bedtime
• Week 5-6: 1.5 mg at bedtime
• Continue increasing by 0.5 mg every 1-2 weeks until reaching 4.5 mg

Some patients respond well at doses below 4.5 mg and may find their optimal dose at 1.5 mg, 3.0 mg, or anywhere in between. The right dose is the one that produces the best symptom relief with the fewest side effects. Starting low and going slow minimizes the chances of initial side effects disrupting sleep or causing other issues.

Why Bedtime Dosing?

LDN is typically taken at bedtime (between 9 PM and midnight) because this timing aligns with the body’s natural endorphin production cycle. Growth hormone and endorphin secretion peak during the early hours of sleep, so taking LDN in the evening maximizes the rebound effect during this window [19].

Some clinicians prescribe morning dosing for patients who experience sleep disturbances with bedtime administration. Both approaches can be effective, and the timing may need to be individualized.

Ultra-Low Dose Naltrexone (ULDN)

A subset of practitioners use ultra-low dose naltrexone (typically 0.001 to 0.1 mg) for different purposes, particularly as an adjunct to opioid therapy for pain management. At these micro-doses, naltrexone may prevent opioid tolerance and enhance analgesic effects without causing withdrawal [20]. This is a distinct application from standard LDN and should not be confused with it.

Side Effects and Safety

LDN has a remarkably favorable side effect profile. The most common side effects are:

• Vivid dreams: The most frequently reported side effect, usually occurring during the first 1-2 weeks and resolving as the body adjusts
• Insomnia or sleep disturbance: Can often be managed by adjusting the timing of the dose or reducing the amount temporarily
• Headache: Typically mild and transient
• Nausea: Occasional, usually resolves within the first week
• Anxiety: Uncommon, but some patients report temporary mood changes during titration

LDN is contraindicated in patients currently taking opioid medications (including tramadol and opioid-containing cough suppressants), as it will block the effects of these drugs and could precipitate withdrawal. Patients on opioids who wish to try LDN must work with their physician to safely taper off opioids first, typically waiting 7 to 14 days after the last opioid dose before starting LDN [2].

There is no evidence of liver toxicity at LDN doses. The liver toxicity warning on standard-dose naltrexone (50 mg) pertains to doses at least 10 times higher than what is used in LDN protocols. Standard blood work monitoring is still reasonable, particularly in patients with pre-existing liver conditions.

How to Get LDN

LDN is not available as a standard commercial medication at the doses used therapeutically (0.5-4.5 mg). The commercially available naltrexone tablet is 50 mg, which is far too large for LDN dosing. Instead, LDN must be obtained through a compounding pharmacy that can prepare it in the correct small doses.

You will need a prescription from a physician, nurse practitioner, or other licensed prescriber. Because LDN is used off-label, not all providers are familiar with it. Integrative medicine physicians, functional medicine practitioners, and some rheumatologists and pain specialists are most likely to be knowledgeable about LDN prescribing.

Compounded LDN typically costs $30 to $60 per month, making it one of the most affordable treatment options in the integrative medicine space. It is available as capsules, liquid formulations, or sublingual preparations depending on the compounding pharmacy.

What to Expect When Starting LDN

Patience is important with LDN. Unlike a pain medication that works within hours, LDN’s benefits build over weeks to months as the endorphin system upregulates and inflammatory pathways quiet down. Most patients begin noticing improvements in 4 to 8 weeks, though some respond more quickly and others may need 3 to 6 months to see the full benefit.

If you experience vivid dreams or sleep disruption in the first week or two, it is generally worth pushing through unless the side effects are severe. These typically resolve on their own. If they do not, reducing the dose by half and titrating more slowly often solves the problem.

LDN is not a cure-all, and it does not work for everyone. In the fibromyalgia studies, roughly one-third of patients were classified as significant responders. But given its excellent safety profile, low cost, and the severity of the conditions it treats, a trial of LDN is often a reasonable step for patients who have not found adequate relief from other therapies.

References

• [1] Gonzalez JP, Brogden RN. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 1988;35(3):192-213. doi:10.2165/00003495-198835030-00002. PMID: 2836152.
• [2] Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459. doi:10.1007/s10067-014-2517-2. PMID: 24526250.
• [3] Bihari B. Bernard Bihari, MD: low-dose naltrexone for normalizing immune system function. Altern Ther Health Med. 2013;19(2):56-65. PMID: 23594453.
• [4] Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses. 2009;72(3):333-337. doi:10.1016/j.mehy.2008.06.048. PMID: 19041189.
• [5] Zagon IS, McLaughlin PJ. Opioid growth factor and the treatment of human pancreatic cancer: a review. World J Gastroenterol. 2014;20(9):2218-2223. doi:10.3748/wjg.v20.i9.2218. PMID: 24605019.
• [6] Watkins LR, Hutchinson MR, Rice KC, Maier SF. The “toll” of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci. 2009;30(11):581-591. doi:10.1016/j.tips.2009.08.002. PMID: 19762094.
• [7] Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008;28(1):20-29. doi:10.1111/j.1460-9568.2008.06321.x. PMID: 18662331.
• [8] Raknes G, Småbrekke L. Low dose naltrexone: effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study. PLoS One. 2019;14(2):e0212460. doi:10.1371/journal.pone.0212460. PMID: 30785919.
• [9] Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663-672. doi:10.1111/j.1526-4637.2009.00613.x. PMID: 19453963.
• [10] Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529-538. doi:10.1002/art.37734. PMID: 23359310.
• [11] Cree BAC, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010;68(2):145-150. doi:10.1002/ana.22006. PMID: 20695007.
• [12] Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16(8):964-969. doi:10.1177/1352458510366857. PMID: 20534644.
• [13] Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn’s disease. Am J Gastroenterol. 2007;102(4):820-828. doi:10.1111/j.1572-0241.2007.01045.x. PMID: 17222320.
• [14] Smith JP, Field D, Bingaman SI, Evans R, Mauger DT. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn’s disease: a pilot study. J Clin Gastroenterol. 2013;47(4):339-345. doi:10.1097/MCG.0b013e3182702f2b. PMID: 23188075.
• [15] Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459. doi:10.1007/s10067-014-2517-2. PMID: 24526250.
• [16] Liesz T. LDN and Hashimoto’s thyroiditis. LDN Research Trust Conference Proceedings. 2018.
• [17] Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science. 1983;221(4611):671-673. doi:10.1126/science.6867737. PMID: 6867737.
• [18] O’Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long covid cohort: an interventional pre-post study. Brain Behav Immun Health. 2022;24:100485. doi:10.1016/j.bbih.2022.100485. PMID: 35814187.
• [19] Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382-389. doi:10.1002/phar.2086. PMID: 29377216.
• [20] Crain SM, Shen KF. Antagonists of excitatory opioid receptor functions enhance morphine’s analgesic potency and attenuate opioid tolerance/dependence liability. Pain. 2000;84(2-3):121-131. doi:10.1016/S0304-3959(99)00223-7. PMID: 10666516.

Related Reading

• LDN for Autoimmune Disease: What Patients and Clinicians Should Know
• The Complete Guide to Low Dose Naltrexone
• Peptide Injections: Types, Technique, and What to Know Before Starting